Last 48 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Sanara MedTech Inc.'s quarterly P/E stands at 84.2x. EV/EBITDA has compressed 60.5% YoY to 14.6x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -5.05 | 84.22 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.96 | 1.39 | 1.83 | 2.69 | 2.37 | 2.82 | 2.69 | 2.97 | 2.96 | 4.20 | 4.96 | 4.05 | 5.24 |
| — | -50.8% | -32.1% | -9.4% | -20.2% | -32.8% | -45.7% | -26.6% | -43.4% | -22.6% | -19.6% | -12.3% | +18.9% | |
| P/B Ratio | 32.02 | 21.99 | 33.96 | 46.26 | 6.91 | 7.22 | 7.28 | 6.53 | 5.77 | 7.24 | 7.87 | 5.88 | 8.05 |
| — | +204.8% | +366.5% | +608.7% | +19.7% | -0.4% | -7.5% | +11.0% | -28.3% | -10.9% | -13.1% | +9.1% | +67.6% | |
| P/FCF | 93.38 | — | 13.03 | 63.50 | 67.72 | — | 84.66 | 31.54 | — | — | — | 72.55 | — |
| — | — | -84.6% | +101.3% | — | — | — | -56.5% | — | — | — | — | — | |
| EV / EBITDA | 19.77 | 14.62 | 16.36 | 22.13 | 63.03 | 37.00 | 60.73 | — | — | — | 102.86 | 727.89 | — |
| — | -60.5% | -73.1% | — | — | — | -41.0% | — | — | — | — | — | — | |
| EV / EBIT | 25.52 | 17.87 | 20.14 | 26.69 | — | 87.40 | — | — | — | — | — | — | — |
| — | -79.6% | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Sanara MedTech Inc.'s operating margin was 9.5% in Q1 2026, down 1.0 pp QoQ and up 6.0 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 7.8% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 90.1% | 91.0% | 90.8% | 90.6% | 92.5% | 89.2% | 91.4% | 90.8% | 90.0% | 89.8% | 89.9% | 89.1% | 86.1% |
| — | +2.0% | -0.7% | -0.3% | +2.7% | -0.7% | +1.7% | +2.0% | +4.6% | +4.1% | +6.3% | +7.4% | -4.4% | |
| Operating Margin | 8.9% | 9.5% | 10.5% | 11.2% | -0.1% | 3.5% | -1.4% | -8.9% | -14.3% | -8.3% | -1.3% | -5.7% | -11.8% |
| — | +170.3% | +836.6% | +226.7% | +99.2% | +142.6% | -11.6% | -56.9% | -20.8% | -5.4% | +93.7% | +77.2% | +66.2% | |
| Net Margin | -36.4% | 1.7% | -5.8% | -115.5% | -7.8% | -15.0% | -5.8% | -13.2% | -17.4% | -9.5% | -1.3% | -6.6% | -11.6% |
| — | +111.0% | +0.1% | -775.8% | +55.1% | -58.1% | -336.2% | -99.3% | -49.8% | -25.4% | +95.0% | +41.3% | -245.8% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -167.5% | 7.1% | -26.7% | -146.5% | -5.6% | -9.3% | -3.9% | -7.1% | -8.3% | -4.0% | -0.5% | -2.5% | -4.4% |
| — | +176.0% | -579.8% | -1972.1% | +32.7% | -131.7% | -634.1% | -183.5% | -87.2% | -42.2% | +94.4% | +32.1% | -284.3% | |
| ROA | -46.7% | 0.6% | -2.2% | -35.8% | -2.1% | -3.8% | -1.7% | -3.5% | -4.9% | -2.4% | -0.3% | -1.6% | -3.1% |
| — | +116.9% | -28.3% | -914.5% | +57.5% | -56.9% | -448.5% | -122.6% | -57.1% | -25.2% | +95.3% | +41.8% | -261.5% | |
| ROIC | 14.8% | 5.0% | 5.7% | 4.3% | -0.0% | 1.1% | -0.5% | -2.7% | -4.2% | -2.2% | -0.3% | -1.6% | -3.8% |
| — | +368.8% | +1218.7% | +260.2% | +99.1% | +147.9% | -51.7% | -72.5% | -9.5% | +14.7% | +95.1% | +81.1% | +73.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Sanara MedTech Inc.'s Debt/EBITDA ratio is 15.0x, up from 13.5x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 17.9% YoY to 2.28x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 8.13 | 6.89 | 8.13 | 7.73 | 1.28 | 1.22 | 0.83 | 0.81 | 0.39 | 0.27 | 0.26 | 0.27 | 0.05 |
| — | +464.9% | +879.5% | +855.2% | +226.6% | +348.4% | +213.7% | +200.9% | +684.5% | +434.1% | +1246.9% | +1285.2% | +476.2% | |
| Debt / EBITDA | 4.08 | 14.96 | 13.54 | 13.27 | 41.97 | 22.93 | 26.17 | — | — | — | 13.57 | 130.29 | — |
| — | -34.8% | -48.3% | — | — | — | +92.8% | — | — | — | — | — | — | |
| Current Ratio | 1.80 | 2.28 | 1.80 | 1.80 | 2.26 | 2.77 | 2.18 | 2.23 | 1.80 | 1.35 | 1.38 | 1.46 | 1.84 |
| — | -17.9% | -17.3% | -19.2% | +25.8% | +105.7% | +57.8% | +51.9% | -2.2% | -24.8% | -14.3% | -34.5% | -35.7% | |
| Quick Ratio | 1.59 | 2.05 | 1.59 | 1.60 | 2.03 | 2.54 | 2.00 | 2.02 | 1.49 | 1.02 | 1.04 | 1.09 | 1.39 |
| — | -19.2% | -20.5% | -20.4% | +36.0% | +149.5% | +92.5% | +85.7% | +7.1% | -30.8% | -22.1% | -40.7% | -44.9% | |
| Interest Coverage | 1.35 | 1.47 | 1.58 | 1.63 | -0.02 | 0.63 | -0.32 | -1.45 | -4.50 | -5.73 | -7.59 | -4.82 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SMTI stock.
Sanara MedTech Inc.'s current P/E is -5.1x. The average P/E over the last 1 quarters is 84.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sanara MedTech Inc.'s current operating margin is 8.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sanara MedTech Inc.'s business trajectory between earnings reports.